Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.47 |
| ▸ | HSPB1 | P04792 | 4/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631602 | 1.00 | TRPA1 (0.47) | TRPA1HSPB1ROCK2CYP3A4MAPT | |
| SCHEMBL20659698 | 0.88 | ROCK2 (0.43) | TRPA1ROCK2CYP3A4MET | |
| SCHEMBL23081494 | 0.87 | HSPB1 (0.44) | TRPA1HSPB1ROCK2CYP3A4MAPT | |
| SCHEMBL29814379 | 0.87 | HSPB1 (0.44) | TRPA1HSPB1ROCK2CYP3A4MAPT | |
| SCHEMBL18548485 | 0.83 | TRPA1 (0.70) | TRPA1HSPB1ROCK2CYP3A4MAPT | |
| SCHEMBL30310264 | 0.82 | HSPB1 (0.44) | HSPB1ROCK2CYP3A4MAPTALDH1A1 | |
| SCHEMBL21777818 | 0.82 | HSPB1 (0.44) | HSPB1ROCK2CYP3A4MAPTALDH1A1 | |
| SCHEMBL30310263 | 0.82 | HSPB1 (0.44) | HSPB1ROCK2CYP3A4MAPTALDH1A1 | |
| SCHEMBL4250011 | 0.82 | MET (0.56) | HSPB1ROCK2CYP3A4MAPTALDH1A1 | |
| SCHEMBL4248999 | 0.81 | MET (0.43) | HSPB1ROCK2CYP3A4MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520416-B | Polysubstituted pyridone derivative, preparation method and medical application thereof | 北京越之康泰生物医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-110520416-A | Polysubstituted pyridine ketones derivant, preparation method and its medical usage | BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD | 2019-11-29 | — | — | CN | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| CN-101027305-A | Fused heterocyclic kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-08-29 | — | — | CN | disclosed |
| CN-101005843-A | Pyrrolotriazine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-07-25 | — | — | CN | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | TRPA1 3765/4885HSPB1 2930/4885ROCK2 395/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | TRPA1 2222/4885HSPB1 2677/4885ROCK2 433/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | TRPA1 3765/4885HSPB1 2930/4885ROCK2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.